Navigating Global Pharma Policy
Navigate the intricate dynamics of tariffs the on global pharmaceutical industry through this insightful content series. With contributions from A&M experts on both sides of the Atlantic, this series explores the economic, operational, and legal challenges posed by international trade policies. From the potential disruption of global supply chains to the strategic responses of leading pharmaceutical companies, A&M's Global Life Sciences team offers a comprehensive analysis of how the industry is navigating this evolving landscape.
Gain valuable perspectives on financial optimization, supply chain resilience, and regulatory compliance, as well as the broader geopolitical implications of these tariffs. Whether you're a stakeholder in the pharmaceutical sector or simply interested in the intersection of trade and healthcare, this series provides actionable insights and thought leadership from professionals deeply embedded in the industry.
Even if it never lands, reform momentum is real, and pharma can’t sit back.
Most-Favored-Nation: Weak Policy, Strong Signal
The MFN wake-up call
MFN may never become law, but its signal still matters
The industry is still parsing the implications of the new MFN framework established by May’s Executive Order. While practical policy details remain undefined, the signal is unmistakable: the administration wants to bring pharma to the table on drug pricing.
The real question is how the industry responds. Does it see MFN as a threat that it must navigate or as an opportunity to lead?
Meeting the moment with practical alternatives
By acknowledging affordability pressures and putting forth workable solutions, the industry can safeguard innovation, rebuild trust, and shape sustainable policy solutions.
Good business practices in an MFN world
Even if MFN is not fully implemented, pharma can’t afford to wait and see. By fortifying portfolios, tightening financial discipline, and reinforcing supply chains, companies can hedge against MFN while building resilience to future policy shocks.
Stay informed as we continue to explore the evolving landscape of U.S. trade policies and their impact on the global pharmaceutical industry. This series will be updated regularly to reflect the latest developments, offering fresh insights and strategies to navigate the challenges ahead. Follow along as we analyze policy shifts, industry responses, and the broader implications for global healthcare and trade.
